Hims & Hers Stock Drops After Earnings: Buying Opportunity or Warning Sign?

Hims & Hers reported Q1 2026 revenue of $608.1 million, up 4% year over year, but profitability weakened sharply with a $92.1 million net loss versus $49.5 million net income a year earlier and adjusted EBITDA down to $44.3 million from $91.1 million. Gross margin compressed to 65% from 73% as the business shifted away from compounded GLP-1 drugs toward lower-margin branded products, and adjusted EBITDA guidance was cut to $275 million-$350 million from $300 million-$375 million. Management still raised full-year revenue guidance to $2.8 billion-$3.0 billion, but shares fell more than 12% on the earnings release.

Analysis

The key read-through is that HIMS is transitioning from a high-margin regulatory arbitrage story to a lower-margin platform build, and that usually causes multiple compression before the market believes the new earnings base. The margin reset is not just a one-quarter issue: branded GLP-1s, diagnostics, AI tooling, and international rollout all add revenue but also drag on contribution margins until scale and utilization catch up, so the next 2-3 quarters are likely to be judged on gross margin trajectory rather than top-line growth alone.

Second-order, the company is becoming more dependent on patient acquisition efficiency just as it broadens the funnel. That makes paid marketing, retention, and prescription conversion the real swing factors; if CAC rises faster than subscriber monetization, operating leverage can flip negative even with strong revenue growth. The most vulnerable investors are those underwriting a near-term re-rating on “growth plus FCF” — the quarter suggests that formula is now broken until management proves it can stabilize unit economics in the new product mix.

On the other hand, the selloff may overstate long-term structural damage because the business is intentionally swapping regulatory risk for commercial execution risk. If management can show that branded weight-loss and adjacent services lower churn, expand lifetime value, and improve cross-sell, the current earnings dip could become a setup for a second inflection in 2027. NVO is a relative winner in the sense that a stronger branded channel validates the category, but it also gains leverage over pricing and supply as the market migrates away from compounded alternatives.

The contrarian view is that the market may be underestimating how quickly a digital health platform can monetize a broader disease stack once the customer base is large enough. The danger is timing: the stock can remain range-bound for months while investors wait for evidence that AI, diagnostics, and international expansion are not just expense lines. In the next 30-90 days, the catalyst list is mostly about whether management can defend guidance while proving the margin trough is near.

Key Decisions for Investors

• Maintain a tactical short/underweight in HIMS for 1-3 months; the near-term asymmetry still favors multiple compression if gross margin stays sub-67% and EBITDA guidance keeps ratcheting lower.
• For investors with existing HIMS exposure, buy downside protection via 3-6 month put spreads; the cleanest risk is another guidance cut or evidence that CAC inflation is outpacing subscriber monetization.
• Pair trade: long NVO / short HIMS over the next 3-6 months to isolate the shift from compounded to branded GLP-1 economics; NVO benefits if the category normalizes around branded supply and pricing power.
• Look to buy HIMS only after a confirmed operating inflection, ideally one quarter of sequential EBITDA stabilization and gross margin inflection; until then, the stock is a “show me” story, not a momentum buy.
• If HIMS selloff overshoots into a valuation dislocation on enterprise-value-to-sales alone, use a small starter long with a 6-12 month horizon and strict stop-loss, because the optionality on international and diagnostics is real but not yet monetized.